Cardio Pharmacogenetics (PGx) Gene Variation Panel
Metabolizing cardiovascular medication occurs via cytochromes produced in the liver. Because of the interindividual variability in metabolizing cardiovascular medication, the dosing of a certain medication can produce different results for patients. Part of this variability can be attributed to genetic factors that affect the activity of cytochromes, the rate of metabolizing medication, and ultimately the efficacy of the prescribed medication. Thus, using PGx testing determines a patient’s genetic makeup, as it pertains to drug metabolism, transportation, and utilization, and offers healthcare providers insight into a patient’s predicted response to a prescribed medication, and improve the precision of treatment.
Depending on laboratory panel design and patient population, Cardio Pharmacogenetics Gene Variation Panel might contain genes associated with few to many targets including ABCB1, ABCG2, APOE, CYP2C, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, F2, F5, ITGB3, MTHFR, SLCO1B1, VKORC1. PGx testing for cardiovascular medication provides genetic information that optimizes medication regimens for patients with heart disease. Healthcare providers can use PGx as a tool to better design a personalized treatment plan for their patients without having to take the trial-and-error approach, which can reduce the event of adverse drug reactions. Therefore, PGx enables safer, more effective, and cost-effective treatment by using genetic information that would help predict drug response, and further guide optimal drug and dose selection.
In addition, to above genes and variation the cardiology PGX panel will include genetic variation of coagulation factors FV, FII and MTHFR used for thrombotic genetic risk evaluation. The panel also includes APOE genetic variation testing for arteriosclerosis and cardiovascular disease and Alzheimer’s disease risk assessment. The genetic variations (mutations) of the above listed genes are tested using PCR based TaqMan® genotyping assay or next generation sequencing assay.
- Evaluation of drug therapy used for cardiovascular diseases and disorders
- Evaluation of thrombotic risk and thrombophilia related diseases
- Evaluation of arteriosclerosis and cardiovascular disease risk assessment
See individual assay.
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- J Pers Med. 2021 Nov 11;11(11):1180. [PMID: 34834533]
- Adv Pharmacol. 2018;83:333-360. [PMID: 29801582]
- Pharmacol Rev. 2013 May 17;65(3):987-1009. [PMID: 23686351]
- Diseases. 2021 Aug 12;9(3):55. [PMID: 34449608]
- Pharmacol Ther. 2013 Apr;138(1):103-41. [PMID: 23333322]
- Drug Metab Rev. 2009;41(2):89-295. [PMID: 19514967]
- Nature. 2015;526(7573):343–50. [PMID: 26469045]
- Mol Diagn Ther. 2013 Jun;17(3):165-84. [PMID: 23588782]
- Biomarkers in medicine vol. 5,4 (2011): 427-38. [PMID: 21861665]
- Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available from URL: http://www.cypalleles.ki.se/cyp2d6.htm